

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is solely for the purpose of reference and does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “**Securities Act**”), or the securities laws of any state of the United States or any other jurisdiction, and may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Accordingly, the Bonds are being offered and sold only outside the United States in offshore transactions in compliance with Regulation S under the Securities Act. This announcement and the information contained herein are not for distribution, directly or indirectly, in or into the United States. No public offer of the securities referred to herein is being or will be made in the United States.*

**NOTICE OF LISTING ON  
THE STOCK EXCHANGE OF HONG KONG LIMITED**

**TAIZHOU ORIENTAL CHINA MEDICAL CITY HOLDING GROUP CO., LTD.**

**(泰州東方中國醫藥城控股集團有限公司)**

*(incorporated with limited liability in the People’s Republic of China)*

**U.S.\$50,000,000 2.10 per cent. Credit Enhanced Bonds due 2024 (the “Bonds”)  
with the benefit of an irrevocable Standby Letter of Credit issued by  
Bank of Nanjing, Taizhou Branch  
(Stock Code: 40846)**

*Placing Agents*

**Fosun Hani**

**Shanghai Pudong  
Development Bank  
Hong Kong Branch**

**Wilson Securities**

**Dongxing  
Securities  
(Hong Kong)**

**Sinolink HK**

Application has been made to The Stock Exchange of Hong Kong Limited for the listing of and permission to deal in the Bonds as described in the Information Memorandum dated 13 September 2021, by way of debt issues to professional investors (as defined in Chapter 37 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited) only. The listing of the Bonds is expected to become effective on 20 September 2021.

Hong Kong, 17 September 2021

*As at the date of this announcement, the directors of Taizhou Oriental China Medical City Holding Group Co., Ltd. (泰州東方中國醫藥城控股集團有限公司) are Mr. ZHANG Lu, Mr. HANG Xiang, Mr. WU Zhiqiang and Mr. DAI Meng.*